https://doi.org/10.4081/itjm.2026.2669
From preclinical evidence to public expectation: ethical and clinical implications of miscommunicated cancer research
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 24 September 2026
Dear Editor,
The communication of preclinical cancer research to the public represents a critical interface between science and clinical practice...
Downloads
Retraction for Liaki et al., A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Proc Natl Acad Sci U S A 2026;123:e2612385123. DOI: https://doi.org/10.1073/pnas.2612385123
Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics, 2025. CA Cancer J Clin 2025;75:10-45. DOI: https://doi.org/10.3322/caac.21871
Begley CG, Ellis LM. Drug development: raise standards for preclinical cancer research. Nature 2012;483:531-3. DOI: https://doi.org/10.1038/483531a
Boutron I, Ravaud P. Misrepresentation and distortion of research in biomedical literature. Proc Natl Acad Sci U S A 2018;115:2613-9. DOI: https://doi.org/10.1073/pnas.1710755115
Ouanes K. Generative artificial intelligence in healthcare: current status and future directions. Ital J Med 2024;18:1782. DOI: https://doi.org/10.4081/itjm.2024.1782
Ioannidis JP. Why most published research findings are false. PLoS Med 2005;2:e124. DOI: https://doi.org/10.1371/journal.pmed.0020124
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.